US stocks fell sharply on Friday as investors digested a mixed January employment report amid an escalation of concerns about a trade war following comments from Donald Trump.

US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday posted its revised Evidence Report assessing the comparative clinical effectiveness and value of ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Following their investor field trip to Berlin ahead of Germany’s election next month, Morgan Stanley (NYSE:MS) strategists ...

Live Updates S&P 500 Nears Record High Amid Tech Redemption 1:31 pm Stocks have reclaimed pre-DeepSeek levels as the S&P 500 looks to close out January higher. The S&P 500 is on pace for a 3%-plus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Uber and Lyft (NASDAQ: LYFT) shares faced pressure this week following a series of autonomous vehicle (AV) developments, including Tesla’s plans for self-drivin ...

Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene ...